Drugs / Ionolyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07823530 | Oct 2026 → Oct 2028 expected | — | University Hospital of Split | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03338218 Comparator | Feb 2019 → Jun 2022 | acute hypotension | Fresenius Kabi | Completed | No outcome recorded |
| Phase 4 | NCT03278548 Comparator | Sep 2017 → Apr 2022 | acute hypotension | Fresenius Kabi | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ionolyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03278548 ↗ |
| Modality | Other / unclassified | “a crystalloid solution (Ionolyte, Fresenius Kabi, Germany)” PMID 35193648 ↗ Feb 2022 |
| Route | Intravenous | “will be randomized to receive intravenous treatment” PMID 35655234 ↗ Jun 2022 |